Nuvation Bio Finalizes Protocol Amendment for Phase 3 Trial of Safusidenib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy NUVB?
Nuvation Bio announced finalization of a protocol amendment to the ongoing global SIGMA study of safusidenib that expands it to a Phase 3 trial. SIGMA is evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-risk or high-grade IDH1-mutant astrocytoma following standard-of-care. Safusidenib is a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1. The new protocol broadens patient eligibility in the registrational portion of the trial and includes those with grades 2 and 3 IDH1-mutant astrocytoma with high-risk features and grade 4 IDH1-mutant astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. The primary endpoint is progression-free survival as assessed by Blinded Independent Central Review per Response Assessment in Neuro-Oncology 2.0
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVB
Wall Street analysts forecast NUVB stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.910
Low
8.00
Averages
11.38
High
18.00
Current: 5.910
Low
8.00
Averages
11.38
High
18.00
About NUVB
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuvation Bio Expands SIGMA Study to Phase 3 Trial
- Clinical Trial Expansion: On February 9, Nuvation Bio announced a protocol amendment to the global SIGMA study, expanding it to a Phase 3 trial aimed at evaluating the efficacy of safusidenib for high-risk IDH1-mutant astrocytoma patients, highlighting the company's potential in oncology treatment.
- Expanded Patient Eligibility: The new protocol broadens patient eligibility in the registrational trial to include grades 2 and 3 IDH1-mutant astrocytoma patients with high-risk features, as well as grade 4 patients post-standard treatment, which is expected to significantly increase participant numbers and enhance the reliability of study outcomes.
- Price Target Increase: Truist raised Nuvation Bio's price target from $11 to $13 on January 27 while maintaining a Buy rating, reflecting strong market expectations for its Ibtrozi product line despite seasonal challenges.
- Diverse R&D Pipeline: Nuvation Bio is advancing several clinical-stage candidates, including a BET inhibitor and a ROS1 inhibitor, demonstrating its diversified strategy in oncology aimed at filling market gaps and enhancing the company's competitive edge.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Surge in Clinical Trials: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, highlighting the drug's potential market value of up to $5 billion in a challenging cancer segment.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, reflecting the company's commitment to expanding its clinical development efforts and enhancing operational capabilities.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Clinical Trial Surge: In 2024, over 2,100 oncology clinical trials were initiated globally, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 10% response rate of standard treatments, which will expedite its approval process.
- Significant Survival Extension: Patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, suggesting a potential market value of $3 billion to $5 billion for this difficult-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expansion plans, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, demonstrating the company's commitment to advancing its clinical development initiatives.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep
- Clinical Trial Surge: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, indicating a potential market value of $3 billion to $5 billion for this hard-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expanding programs, demonstrating the company's commitment to accelerating product development and enhancing management capabilities for future clinical trials.
See More
Nuvation Bio (NUVB) Shares Hit Oversold Territory with RSI at 29.5
- Oversold Signal: Nuvation Bio (NUVB) shares have fallen to $6.315, with an RSI of 29.5, indicating that the recent heavy selling may be nearing exhaustion, thus providing potential buying opportunities for bullish investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 67.4, NUVB's oversold condition may attract investor attention, particularly in the context of overall strong market performance, highlighting its relative value appeal.
- Historical Performance: NUVB's 52-week low is $1.54 and high is $9.75, with the current trading price at $6.46, suggesting significant upside potential amidst volatility, which may attract investors looking for a rebound.
- Investor Sentiment: The current oversold status may prompt investors to reassess NUVB's potential value, especially after a significant price drop, potentially sparking renewed interest in the stock.
See More
Seeking Alpha Releases Q4 Stock Ratings, Micron and Others Rated Strong Buy
- Quant Model Performance: Seeking Alpha's Quant model has consistently outperformed the S&P 500, leveraging powerful computational capabilities and a unique 'Quantamental' analysis to enhance investor decision-making efficiency.
- Earnings Growth Expectations: FactSet estimates an 8.3% year-over-year earnings growth for the S&P 500 in Q4, which, if realized, would mark the index's tenth consecutive quarter of earnings growth, indicating market resilience and sustained corporate profitability.
- Top-Rated Stocks: According to Seeking Alpha's quant model, stocks like Micron Technology and Lumentum Holdings received a strong buy rating of 4.99, suggesting these companies excel in value, growth, and profitability metrics, potentially attracting more investor interest.
- Lowest-Rated Stocks: Stocks such as Fermi and Ørsted are rated as strong sells with quant scores as low as 1.00, reflecting a pessimistic outlook on their earnings prospects and prompting investors to reassess their portfolios.
See More
Nuvation Bio Expands SIGMA Study to Phase 3 Trial
- Clinical Trial Expansion: On February 9, Nuvation Bio announced a protocol amendment to the global SIGMA study, expanding it to a Phase 3 trial aimed at evaluating the efficacy of safusidenib for high-risk IDH1-mutant astrocytoma patients, highlighting the company's potential in oncology treatment.
- Expanded Patient Eligibility: The new protocol broadens patient eligibility in the registrational trial to include grades 2 and 3 IDH1-mutant astrocytoma patients with high-risk features, as well as grade 4 patients post-standard treatment, which is expected to significantly increase participant numbers and enhance the reliability of study outcomes.
- Price Target Increase: Truist raised Nuvation Bio's price target from $11 to $13 on January 27 while maintaining a Buy rating, reflecting strong market expectations for its Ibtrozi product line despite seasonal challenges.
- Diverse R&D Pipeline: Nuvation Bio is advancing several clinical-stage candidates, including a BET inhibitor and a ROS1 inhibitor, demonstrating its diversified strategy in oncology aimed at filling market gaps and enhancing the company's competitive edge.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Surge in Clinical Trials: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, highlighting the drug's potential market value of up to $5 billion in a challenging cancer segment.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, reflecting the company's commitment to expanding its clinical development efforts and enhancing operational capabilities.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Clinical Trial Surge: In 2024, over 2,100 oncology clinical trials were initiated globally, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 10% response rate of standard treatments, which will expedite its approval process.
- Significant Survival Extension: Patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, suggesting a potential market value of $3 billion to $5 billion for this difficult-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expansion plans, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, demonstrating the company's commitment to advancing its clinical development initiatives.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep
- Clinical Trial Surge: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, indicating a potential market value of $3 billion to $5 billion for this hard-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expanding programs, demonstrating the company's commitment to accelerating product development and enhancing management capabilities for future clinical trials.
See More
Nuvation Bio (NUVB) Shares Hit Oversold Territory with RSI at 29.5
- Oversold Signal: Nuvation Bio (NUVB) shares have fallen to $6.315, with an RSI of 29.5, indicating that the recent heavy selling may be nearing exhaustion, thus providing potential buying opportunities for bullish investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 67.4, NUVB's oversold condition may attract investor attention, particularly in the context of overall strong market performance, highlighting its relative value appeal.
- Historical Performance: NUVB's 52-week low is $1.54 and high is $9.75, with the current trading price at $6.46, suggesting significant upside potential amidst volatility, which may attract investors looking for a rebound.
- Investor Sentiment: The current oversold status may prompt investors to reassess NUVB's potential value, especially after a significant price drop, potentially sparking renewed interest in the stock.
See More
Seeking Alpha Releases Q4 Stock Ratings, Micron and Others Rated Strong Buy
- Quant Model Performance: Seeking Alpha's Quant model has consistently outperformed the S&P 500, leveraging powerful computational capabilities and a unique 'Quantamental' analysis to enhance investor decision-making efficiency.
- Earnings Growth Expectations: FactSet estimates an 8.3% year-over-year earnings growth for the S&P 500 in Q4, which, if realized, would mark the index's tenth consecutive quarter of earnings growth, indicating market resilience and sustained corporate profitability.
- Top-Rated Stocks: According to Seeking Alpha's quant model, stocks like Micron Technology and Lumentum Holdings received a strong buy rating of 4.99, suggesting these companies excel in value, growth, and profitability metrics, potentially attracting more investor interest.
- Lowest-Rated Stocks: Stocks such as Fermi and Ørsted are rated as strong sells with quant scores as low as 1.00, reflecting a pessimistic outlook on their earnings prospects and prompting investors to reassess their portfolios.
See More
